The finding that the HIF-PH inhibitor dose had to be increased or decreased in some patients indicates that Hb needs to be monitored in all patients on HIF-PH inhibitors and drug doses need to be adjusted so that the level is maintained at 11 to about 13 g/dL to prevent the onset of thromboembolism. Here, GSTM1 is linked to Thromboembolism.